Blog

DEEP RESEARCH · AUTOIMMUNE BIOTECH

Korean Autoimmune Biotech Platform and Pipeline Comparison

A peer review of AprilBio, HanAll Biopharma, and GI Innovation across platform quality, commercialization, balance sheet, and catalysts

Published: 2026-02-28 · Biotech peer-group analysis · Naver Blog

Investment decisions are your own responsibility. This material is research and is not a recommendation to buy or sell.

0. Bottom line first

Among the three companies, I view AprilBio as having the strongest risk-reward today. The thesis is the overlap of SAFA clinical validation, next-generation APB-A1 and APB-R3 mechanisms, roughly KRW 70bn in cash-like assets, and the APB-A1 Phase 1b catalyst expected in Q2 2026.

Source image comparing autoimmune biotech companies

1. Platform competitiveness

Official fact: The source compares AprilBio’s SAFA, HanAll Biopharma’s FcRn inhibitor mechanism, and GI Innovation’s GI-SMART platform.

AprilBio

SAFA·REMAP

SAFA extends half-life through serum-albumin binding and supports convenience improvements such as IV-to-SC and weekly-to-monthly dosing. REMAP points to multi-specific antibodies, ADCs, solid tumors, and MASH.

HanAll

FcRn inhibition

The mechanism blocks pathogenic IgG recycling and promotes autoantibody degradation. Batoclimab and IMVT-1402 aim to improve first-generation safety issues.

GI Innovation

GI-SMART

The platform uses protein fusion and linker design. GI-301 is positioned as an IgE Trap with stronger binding than Xolair in the source narrative.

Autoimmune platform scorecardPlatform → pipeline → clinical data → cash runway
MechanismCD40L·IL-18·FcRn·IgE
FormulationSC·half-life extension
PartnersLundbeck·Evommune·Immunovant·Yuhan
FinanceRunway·dilution risk
The key is whether platform value turns into human efficacy data.

2. Pipeline and market potential

In TED, the source compares APB-A1 (CD40L), Tepezza (IGF-1R), and batoclimab (FcRn). It notes Tepezza generated USD 1.9bn in 2024 sales and USD 381mn in Q1 2025, while safety issues such as hearing loss and IV administration burden remain.

In atopic dermatitis, APB-R3 targets IL-18 against Dupixent’s IL-4/13 axis and non-responder limitations. The source says Evommune’s February 2026 APB-R3 Phase 2a result showed up to a 34% EASI reduction.

CompanyCore assetsSource catalystsMain risk
AprilBioAPB-A1, APB-R3, SAFA/REMAPQ2 2026 APB-A1 TED Phase 1b, H2 2026 APB-R3 Phase 2bEarly clinical data still needs confirmation
HanAll BiopharmaBatoclimab, IMVT-1402H1 2026 TED global Phase 3, 2027 Graves/MG eventsExpectations and safety management
GI InnovationGI-301CSU Phase 2 progress, need for additional L/OLack of near-term late-stage readout
Source image comparing autoimmune pipelines

3. Finance and valuation

Interpretation: In biotech investing, I put more weight on data and cash runway than scientific appeal alone. AprilBio’s roughly KRW 70bn in cash-like assets and partner milestones reduce dilution risk. HanAll has a commercial cash cow with 2025 revenue of KRW 155.2bn. GI Innovation still carries valuation risk from a large rights offering despite milestone income.

  • The key check is APB-A1 patient efficacy and safety.
  • HanAll has greater commercialization visibility if late-stage trials succeed, but expectations are high.
  • GI Innovation needs GI-301 Phase 2 progress and a new licensing event.

4. Final view

My top pick is AprilBio, based on financial downside support, SAFA platform validation, CD40L/IL-18 next-generation targets, and a dense 2026 data calendar.

Sources

Naver original